Directory · FR
Biotechnology in France
A register of firms and the professionals working at them in the Biotechnology sector based in France. Browse the public index, then filter or export on Kipplo.
Companies
270 on file
Genfit
GENFIT, a BCorp™ certified company since 2025, is a biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Its capacity to develop high potential assets, from early-stages to late development and pre-commercialization stages, is illustrated through the successful 52-week readout of its Phase 3 trial (ELATIVE®) evaluating elafibranor in Primary Biliary Cholangitis (PBC). Today, GENFIT has a diversified R&D pipeline covering several therapeutic areas: five programs in acute on chronic liver failure (ACLF) are in clinical stages (Phase 2) and pre-clinical stages, including hepatic encephalopathy (HE), one of the main complications of ACLF; a Phase 2 clinical program targeting cholangiocarcinoma; and a preclinical program targeting urea cycle disorders (UCD) and organic acidemias (OA). GENFIT’s pipeline also includes a diagnostic franchise focused on Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis or NASH) and ammonia. GENFIT has facilities in Lille and Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). GENFIT is a publicly traded company listed on compartment B of Euronext’s regulated market in Paris ( Euronext: GNFT). In 2021, IPSEN became one of GENFIT’s largest shareholders and holds 8% of the company’s share capital.
51 to 200 staff
Devyser
Devyser. A new level of certainty We’re specialists when it comes to diagnostic kits for complex DNA testing within oncology, hereditary diseases and transplantation. Our products are used to guide targeted cancer therapies, to enable rapid prenatal diagnostics, as well as in post transplant follow-up. We have a guiding principle when it comes to developing products that are ideal for routine diagnostics: make the technology simple, reproducible and less prone to user-generated errors. And this is precisely what our customers appreciate about us, which is why routine diagnostic laboratories in more than 60 countries worldwide use our products.
51 to 200 staff
Greentech
Our Credo We are biotech pioneers, we are scientists, we are explorers. Working across all continents, in all climates, in all of the worlds’ oceans. We create high-tech active ingredients from natural sources from plant, marine and microbial worlds. We source the best that nature has to offer, to the benefit of everyone: in cosmetics, healthcare, human and animal nutrition, agronomy and environment. We operate worldwide to build sustainable subsidiaries that are founded on the principles of protecting biodiversity and human relationships. No nature, no future! Nature is a source of inspiration, source of information, the source of our technologies. We source nature to resource the future. Wo We Are Pioneer in biotechnology, GREENTECH Group creates high-tech active ingredients from natural sources from plant, marine and microbial worlds. Adressed to major markets (cosmetics, healthcare, human & animal nutrition, agronomy and environment) the GREENTECH Group’s innovations represent proven, healthy and sustainable alternatives, serving future generations.
51 to 200 staff
Abbelight
Founded in 2016, Abbelight is a fast-growing company specialized in imaging solutions focusing on microscopy and unique single molecule detection (super-resolution). The portfolio integrates a constantly evolving knowhow on chemistry, optics and computer science to offer a complete solution, from sample preparation to data management, including an optimal bio-imaging platform that can be adapted to all researchers’, biotech labs’ and medical facilities’ needs. Abbelight is a French company developed by four passionate researchers who aim to help improve human health in various areas such as bacteriology, extracellular vesicles, neurosciences, structural biology. Today, Abbelight employs over 60 people who are all driven by the goal of providing the best solutions and support to our customers all around the Créée en 2016, Abbelight est une société en forte croissance spécialisée dans le développement de solutions complètes de microscopie et de nanoscopie (SMLM). Son portfolio intègre un savoir-faire en constante évolution alliant la chimie, l’optique et l’ingénierie informatique. Ainsi, la plate-forme de bio-imagerie proposée permet aux chercheurs des instituts de recherche publiques et aux biotechs, d’optimiser leurs préparations d’échantillons, l’acquisition et la gestion de leurs données grâce à un panel de techniques avancées adaptées à différentes applications. Abbelight est une société française fondée par quatre chercheurs passionnés, qui s’engage à contribuer à l’amélioration de la santé humaine dans de nombreux domaines tels que la bactériologie, les vésicules extracellulaires, les neurosciences, la biologie structurelle… Aujourd’hui, Abbelight emploie plus de 60 collaborateurs, tous animés par la volonté de fournir les solutions de recherches innovantes et d’accompagner ses clients à travers le monde.
11 to 50 staff
Alliance Bio Expertise
ALLIANCE BIO EXPERTISE crée, fabrique et distribue des solutions innovantes pour les laboratoires du monde entier, dans les domaines de la microbiologie et de l'environnement contrôlé. Jour après jour, l'équipe ABE met toute son expérience et son expertise à votre service, pour vous offrir des solutions sur-mesure et clef en main dans les secteurs cosmétique, agro-alimentaire, pharmaceutique, clinique, ainsi que la recherche. Vos challenges sont nos solutions!
11 to 50 staff
Erbc
ERBC is a 50 years’ leading CRO committed to bridge the gap between preclinical and clinical research by better predicting the efficacy and safety of new compounds offering innovative in vitro and in vivo translational models and services. Offering a comprehensive range of experimental capabilities, preclinical models, regulatory pre-IND package and consultancy services, ERBC allows biopharmaceutical and chemical industry professionals to de-risk innovation and enhance R&D productivity. With highly qualified teams, ERBC is offering a customer-centric approach while committed in improving all aspects of study design and conduct applying alternatives to animal testing as a priority.
201 to 500 staff
Andermatt France
Jardiner, cultiver avec des solutions respectueuses de notre environnement Andermatt France est une PME franco-suisse innovante dédiée à 100% au Biocontrôle et à l'Agriculture Biologique. Nous concevons, fabriquons et mettons en marché des solutions alternatives à la chimie conventionnelle pour l'agriculture, les jardins et les espaces verts pour les professionnels et les particuliers. Notre ambition : remplacer les produits de la chimie de synthèse (pesticides, engrais ou biocides) par des alternatives d'origine naturelle. Notre recherche est au service d'une alimentation saine, dans un environnement préservé.
11 to 50 staff
Astraveus
We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies.
51 to 200 staff
Cellenion
Cellenion offers solutions and technologies for controlled cell dispensing with applications in the fields of single-cell isolation and bioprinting : Ability to manipulate single-cell has long been a challenge for the scientific community due to their micrometric size and delicate nature. Cellenion has developed and patented CellenONE, a breakthrough single cell isolation and dispensing technology. CellenONE provides outstanding single cell precision, high throughput, and unmatched recovery. Bioprinting is the process of generating spatially-controlled cell patterns using 3D printing technologies. Cellenion will aim toward both miniaturization and automation in order to produce reproducible models of different complexities.
11 to 50 staff
Transgene
Cancer immunotherapy Transgene (Euronext: TNG) is a clinical stage biotechnology company focused on individualized therapeutic vaccines
51 to 200 staff
Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Abivax also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease. Obefazimod is an investigational, orally administered, once-daily therapy, which we believe has the potential to be a differentiated treatment option for inflammatory bowel diseases. It is the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. If approved, this therapy has the potential to establish a new therapeutic class currently being referred to as miR-124 enhancers.
51 to 200 staff
Ariana Pharma
Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Ariana routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Ariana helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Ariana has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012.
11 to 50 staff
Biomemory
Biomemory is a deep-tech company specialized in enterprise data storage. It leverages molecular engineering to build cost-effective and energy-efficient exabyte rackable appliances for Data Centers. Biomemory also develops high-quality DNA-based anti-counterfeiting systems with minimal ecological impact. Contact us: contact@biomemory.com Jobs and internships: jobs@biomemory.com
11 to 50 staff
Fermentalg
About Fermentalg: Based in Libourne (France), Fermentalg is an industrial biotechnology company, specialized in the production of oil rich in fatty acids (omega-3), proteins and natural pigments (phycocyanin) by fermentation of microalgae. Fermentalg offers innovative products in the global market such Food, Feed and Environment. Fermentalg shares are listed on Euronext in Paris (FR0011271600 - FALG). For more information, À propos de Fermentalg : Basée à Libourne (France), Fermentalg est une société de biotechnologie industrielle, spécialisée dans la production d’huiles riche en acides gras (oméga-3), de protéines et de pigments naturels (phycocyanine) par fermentation de microalgues. Fermentalg propose des produits innovants pour les marchés mondiaux tel que l’alimentation humaine et animale et l'environnement. L’action Fermentalg est cotée sur Euronext à Paris (FR0011271600 - FALG). Plus d’informations :
51 to 200 staff
Grosseron Sas
L’activité de Grosseron est essentiellement basée sur le négoce et la distribution d’équipements, consommables, réactifs et mobiliers de laboratoire. Nous sommes devenus l’un des acteurs majeurs dans ce domaine et réalisons plus de 50 millions d’Euros de chiffre d’affaires. Nous travaillons avec plus de 500 fournisseurs et tenons en stock plus de 100 références réparties en huit gammes spécifiques - Matériel - Produits chimiques - Microbiologie - Biotechnologies - HACCP - Hygiène et sécurité - Mobilier - Prélèvement Grosseron est une entreprise connectée, agile, capable de s'adapter en permanence aux attentes de ses clients et fournisseurs, et ce depuis 130 ans.
51 to 200 staff
Groupe Carso
Leader des prestations analytiques environnementales et agroalimentaires accrédité COFRAC, agréé par le Ministère de la santé Votre environnement et votre santé sont nos priorités. MISSIONS :+ Préserver la santé et contrôler notre environnement. Faire que la population ne court aucun danger dans sa consommation quotidienne et son environnement.+ Travailler en partenariat avec les Agences régionales sanitaires, les agences de l'eau, la grande distribution. DESCRIPTION :+ Matrice Eaux de consommation et sanitaires + Matrice des produits agro alimentaires que vous consommez + Matrices de l'air que vous respirez + Matrice sols + Analyse génétique sur les scènes de crime "section médico légale"+ Analyse des substances dangereuses + Analyse des OGM + Analyse des Dioxines + Analyse Hallal "recherche de présence de porc dans les aliments par génétique"+ Analyse de la radioactivité + Analyse des maladies génétiques + Essais Ecotox, Matériaux aux contacts de l'eau, amiante, Traces organiques, inorganiques.
1001 to 5000 staff
Inovotion
INOVOTION is a biotech company which offers you a unique in vivo technology dedicated to anti-cancer treatment evaluations and early toxicity studies. Our Fast, Sensitive, Reliable and Affordable assay will save you time and money, to give you a clear competitive advantage. This breaking-thought technology, based on chick embryo, provides early analysis of your treatments before the classical preclinical stages. By eliminating low-value molecules early, INOVOTION accelerates your drug discovery process, increases your R&D productivity and reduces its costs. It’s rapid Go/No Go decision with multi-cancer screening capacities. This next generation of in vivo efficacy and toxicity tests covers fours main aspects- EFFICACY assays for your anti-cancer treatments - EARLY TOXICITY assays for your drug candidates - TARGET VALIDATION in oncology - MULTI-CANCER SCREENING to (re)positioning your treatment We help chemists and biologists from companies and universities to validate a target and develop treatments by getting them through in vivo evaluation, while staying within their budget. These accessible efficacy and toxicity assays open really new perspectives of screening for wide variety of project researches with a rapid Go/No Go decisions. You want focus your R&D on your high-value molecules, contact us!
11 to 50 staff
Mabqi
Mabqi specializes in the discovery and development of human therapeutic antibodies. Our core technology is based on proprietary synthetic fully human libraries including pH-sensitive variants tailored for oncology applications. The company offers end-to-end discovery solutions, from antibody discovery, affinity maturation to optimization and full characterization, ensuring tailored support and delivery of high-quality and developable antibodies to meet your needs. Moreover, based on our know-how and technologies, Mabqi is committed to the discovery of therapeutic antibodies on innovative targets with off-the-shelf antibody assets available for partnered development and licensing opportunities.
11 to 50 staff
Phaxiam Therapeutics
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
51 to 200 staff
Phoenix Pharmaceuticals, Inc
Phoenix Pharmaceuticals is a business-to-business (B2B) peptide wholesaler. We manufacture ELISA kits, Peptides, Antibodies and provide Custom Peptide Synthesis. All products made at our laboratory in Silicon Valley, CA. Our customers are scientific researchers, academic labs, and biotech/pharma doing preclinical research and drug development.
11 to 50 staff
Acticor Biotech
Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less that 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains. This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus and Prof. P. Billiald. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France. The project also won the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly Oseo).
11 to 50 staff
Aqualeha
Avec ses expertises, AQUALEHA vous propose une palette de services pour prévenir l’ensemble des risques alimentaires, de sécurité ou environnementaux pour la protection des biens et des personnes.
201 to 500 staff
Biodevas Laboratoires
Recherche, développement et commercialisation des solutions naturelles. Secteur d’activité: Production végétale et animale. Nos produits sont à base des extraits de plantes aromatiques. Mode d'action: Gestion des stress abiotiques et biotiques par une régulation enzymatique. Intérêt: Réduction des intrants chimiques de protection. Profile: Sans résidus, sans délai avant récolte ou d’abattage, utilisable en agriculture biologique.
11 to 50 staff
Aviwell
Aviwell operates at the convergence of DIGITAL & LIFE SCIENCES. Our mission is to develop natural and sustainable solutions to improve animal health to better nourish and provide FOOD SECURITY to the nearly 8 billion people on our planet. And to do so a fraction of the cost. We are a deep-tech startup with our HQ in Toulouse, France and with sales offices in Boston, USA. The company is based on three disruptive assets: • Proprietary biostatistical algorithms, • Extensive microbiology and physiology expertise, and • Native and Adaptive Biomimicry When combined, we are able to develop revolutionary feed solutions for farmers that significantly improve animal growth and health. Aviwell aims to market these unique products on a global market.
1 to 10 staff
